PURE Bioscience develops and commercializes bioscience technologies. The company's flagship bioscience technology is an aqueous antimicrobial called silver dihydrogen citrate (SDC). Of the two analysts covering the stock, 50% recommend a buy while the remaining rate holding. As per the consensus estimates of analysts polled by Bloomberg, the stock has an implied upside of 161.2% and is currently trading at $2.01.
4 Stocks Under $5 With Upside
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.